EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引：2

作者：

Mease, P. J. ^{[1
,2
]}

Deodhar, A. ^{[3
]}

Van der Heijde, D. ^{[4
]}

Behrens, F. ^{[5
]}

Kivitz, A. ^{[6
]}

Lehman, T. ^{[7
]}

Wei, L. ^{[8
]}

Nys, M. ^{[9
]}

Banerjee, S. ^{[10
]}

Nowak, M. ^{[11
]}

机构：

[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[3] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA

[4] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands

[5] Goethe Univ, Translat Med & Pharmacol ITMP, CIRI Rheumatol & Fraunhofer Inst, Frankfurt, Germany

[6] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[7] Bristol Myers Squibb, Rheumatol, Princeton, NJ USA

[8] Bristol Myers Squibb, Med Immunol, Princeton, NJ USA

[9] Bristol Myers Squibb, GBS Biostat, Braine Lalleud, Belgium

[10] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA

[11] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷

关键词：

D O I：

10.1136/annrheumdis-2021-eular.2653

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0227

引用

页码：137 / 138

页数：2

共 50 条

[21] Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial
Eder, Lihi
Ogdie, Alexis R.
Banerjee, Subhashis
Nowak, Miroslawa
Lehman, Thomas
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 945 - 947
[22] SAFETY AND EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A RANDOMISED PHASE 2 TRIAL
Mease, P. J.
Deodhar, A.
Van der Heijde, D.
Behrens, F.
Kivitz, A.
Neal, J.
Nys, M.
Lehman, T.
Delev, N.
Korish, S.
Nowak, M.
Banerjee, S.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 842 - 843
[23] IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL
Gottlieb, A. B.
Armstrong, A.
Merola, J. F.
Napoli, A.
Nowak, M.
Banerjee, S.
Lehman, T.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1145 - 1146
[24] Efficacy of ixekizumab in patients with psoriatic arthritis: Results of a phase 3 randomized, double-blind, active- and placebo-controlled study
Mease, Philip
van der Heijde, Desiree
Ritchlin, Christopher
Cuchacovich, Rachel
Shuler, Catherine
Lin, Chen-Yen
Vangerow, Harald
Samanta, Suvajit
Lee, Chin
Gladman, Dafna
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[25] Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
Schett, Georg
Wollenhaupt, Jurgen
Papp, Kim
Joos, Rik
Rodrigues, Jude F.
Vessey, Adele R.
Hu, ChiaChi
Stevens, Randall
de Vlam, Kurt L.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : 3156 - 3167
[26] Efficacy and safety of oral tolvaptan in patients undergoing hemodialysis: a Phase 2, double-blind, randomized, placebo-controlled trial
Ogata, Hiroaki
Shimofurutani, Naoko
Okada, Tadashi
Nagamoto, Hisashi
Akizawa, Tadao
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (06) : 1088 - 1097
[27] BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS
Fitzgerald, O.
Gladman, D. D.
Mease, P. J.
Ritchlin, C. T.
Smolen, J. S.
Gao, L.
Hu, S.
Nowak, M.
Banerjee, S.
Catlett, I.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 215 - 216
[28] Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis
FitzGerald, Oliver
Gladman, Dafna
Mease, Philip J.
Ritchlin, Christopher
Smolen, Josef
Gao, Lu
Hu, Sarah
Nowak, Miroslawa
Banerjee, Subhashis
Catlett, Ian M.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4229 - 4230
[29] EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR)
Helliwell, P.
Van den Bosch, F.
Coates, L. C.
Gladman, D. D.
Tasset, C.
Meuleners, L.
Gilles, L.
Gheyle, L.
Trivedi, M.
Alani, M.
Besuyen, R.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 761 - 762
[30] Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
Genovese, Mark C.
Spindler, Alberto
Sagawa, Akira
Park, Won
Dudek, Anna
Kivitz, Alan
Chao, Jeannie
Chan, Lai Shan Melanie
Witcher, Jennifer
Barchuk, William
Nirula, Ajay
JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 969 - 976

← 1 2 3 4 5 →